Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. With its diverse product line and focus on key growth areas, the company is well-positioned for continued revenue growth. Additionally, its recent financial performance demonstrates improving profitability and positive investor sentiment, making it an attractive stock for investors in the healthcare sector.

Bears say

AtriCure is facing headwinds in its minimally invasive ablation platform due to PFA-related challenges which continue to decline year-over-year. Additionally, the company remains cautious in terms of its outlook for 2026 due to the ongoing decline in its U.S. hybrid business. There is potential for upside if the company sees stronger adoption of its new products and improvement in margin and EBITDA growth, as well as an increase in free cash flow.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.